Introduction
Glioma is the most frequent and deadliest primary malignant brain neoplasm in humans and accounts for more than 40% of all adult brain tumors. 1 The WHO has categorised four major grades of gliomas, and one of the most common symptoms of these tumours is epilepsy. 2 Although gross-total resection is an effective control measure for glioma-related epileptic activity, approximately 30% of glioma patients with a history of preoperative seizures do not achieve satisfactory seizure prognoses, 3 which significantly affects the glioma patients' quality of life and makes it difficult for these patients to return to work and society. Thus, glioma-associated epilepsy (GAS) is an important clinical issue that requires the care of neurosurgeons. Nonetheless, the medical treatment of these seizures is often met with limited success due to the currently incomplete understanding of their aetiology. Surprisingly, at present, there are no specific GAS guidelines to aid neurosurgeons in prescribing antiepileptic drugs (ADEs) for post-surgery glioma patients; instead, the choice of prescriptions is based on the neurosurgeons' personal preferences and clinical experiences. Enzyme-inducing antiepileptic drugs (EI-AEDs), such as phenytoin and carbamazepine, remain the first-line AEDs prescribed by neurosurgeons for the control of GAS; however, the side effects have been reported to occur with high incidence.
control seizure activity through anti-tumour effects. 5, 6 Non-EIAEDs are not metabolised by the P450 system and may involve other unexpected interactions that do not involve known pathways; hence, recent articles favour the use of valproic acid or newer anticonvulsants, such as lamotrigine and levetiracetam, over the use of carbamazepine and phenytoin. 7 Phenytoin, carbamazepine, sodium valproate, and levetiracetam are the most frequently used AEDs in clinical settings for the treatment or prevention of seizure activity in post-surgery glioma patients. Furthermore, the co-administration of AEDs and chemotherapy agents is often recommended by neurosurgeons. 8 The effectiveness of EI-AEDs compared to that of non-EI-AEDs in the treatment of epilepsy in glioma patients in uncertain. Many clinical trials have produced various results regarding the effectiveness of these two types of drugs. Tracey and his colleagues noted that both levetiracetam (LEV) and phenytoin (PHY) are associated with a low risk of early postoperative seizures and a moderate risk of later epilepsy. 9 In contrast, a randomised controlled trial reported better long-term outcomes with LEV after neurosurgical injury compared with phenytoin. 10 To the best of our knowledge, even though the answer to this question is important for patients requiring chemotherapy, the available research studies that compared the efficacies of EI-AED and non-EI-AEDs for the treatment of post-surgery glioma patients have not been systematically analysed.
With the aim of summarising the evidence on P450 enzymeinducing and non-enzyme-inducing antiepileptic drugs in the prophylactic treatment of seizures according to multiple tumour sub-types, we combined and analysed all of the published data using a meta-analytic approach.
Methods

Search strategy
In October 2013, a bibliography search of the EMBASE, MEDLINE, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials databases was conducted to identify potentially relevant articles and conference abstracts that compared the effects of P450 enzyme-inducing and non-enzyme-inducing antiepileptic drugs in the prophylactic treatment of seizures after glioma resection surgery. Because enzyme-inducing and nonenzyme-inducing AEDs are two large, dichotomous classes of drugs, we selected the four AEDs that are most frequently used as prophylactics for glioma-associated seizures (i.e., phenytoin, carbamazepine, sodium valproate, and levetiracetam). The search was limited to studies written in English. Two investigators (Y.Y and M.YH) independently evaluated the papers according to the inclusion and exclusion criteria, and any controversies were settled by discussion and consensus. The references contained in the identified trials were also examined to identify any other relevant published or unpublished articles. We used combinations of the following search terms: phenytoin, carbamazepine, sodium valproate, levetiracetam, glioma, and brain tumour (details of the search rules are provided in Supplemental file 1).
Inclusion and exclusion criteria
The inclusion criteria were the following:
(a) Because drug use may involve ethical issues and limited RCTs, all comparative studies (i.e., trial, cohort, case-control, and observational studies) of the relevant ADEs were included; (b) The glioma cases were histological confirmed, and all of the included patients had undergone surgery;
(c) The articles provided post-surgery seizure outcomes, and the data included at least the seizure activity records after surgery. The agreed minimum length of the follow-up period should be at least 6 months; and (d) The odds ratios (ORs) or relative risks (RRs) and the 95% confidence intervals (CIs), or sufficient raw data to calculate these variables, were provided.
We excluded studies for the following reasons:
(i) The RR and/or OR data were not available or insufficient to conduct a meta-analysis; (ii) The patients had only received a biopsy or chemotherapy; and (iii) The article type was a letter, editorial, or review.
Data extraction
The first two authors (Y.Y. and M.YH) extracted the following data from each eligible article using a standardised form. Any disagreements were resolved through discussion or consultation with another author (M.Q.). The study designs, patient characteristics, operational definitions, seizure outcomes, ORs, RRs, and 95% CIs were extracted from the articles. We also sent emails to the corresponding authors requesting any missing information as appropriate.
Statistical analyses
Our primary outcome was the efficacy of seizure control. We conducted meta-analyses when data were available from more than one study. The odds ratios (ORs) or risk ratios (RRs) with the 95% confidence intervals presented in the studies were used to estimate the pooled risk. The heterogeneities of the studies were assessed using the Cochran's Q statistic and the I 2 statistic. When the p value was at most 0.1 and the I 2 value was greater than 50%, the heterogeneity was considered significant. Publication biases were estimated using Egger's tests, and p values less than 0.005 were considered evidence of publication bias. All of the p values were two-sided, and all of the analyses were performed using STATA version 11 (STATA/SE, College Station, TX). Because the characteristics of the eligible patients, study designs, glioma malignancy levels, and adjustments for confounding factors were not consistent across the articles, we performed further subset and sensitivity analyses to explore all possible explanations for this heterogeneity and to assess the potential effects of these variables on the outcomes. Fig. 1 shows the flow diagram of the electronic literature search and the selection of articles. A total of 8538 unique publications were identified after the exclusion of duplicates, and the titles or abstracts of these articles were examined to exclude the unrelated studies. Ultimately, 172 relevant articles were identified as primary studies, and the full texts of these articles were retrieved. We then identified eight studies as eligible for our meta-analysis. The authors of these studies were contacted for further information if the data presented in the article was insufficient for our needs. The meta-analysis was ultimately based on six studies (five observational and 1 RCT; this information is summarised in Table 1) . 4, 9, [11] [12] [13] [14] Four of the studies were conducted in North America, one was conducted in Asia, and one was conducted in Table 2 ). Table 1 displays the characteristics of the six studies that were included in our meta-analysis. Overall, the majority of the 845 patients who were included had been diagnosed with glioma (WHO grade II-IV), and the patients had most commonly been diagnosed with WHO grade II glioma. The largest cohort study was conducted by Gan et al. and included 445 WHO grade II glioma patients.
Results
Search results and study characteristics
Outcomes
The follow-up period of all of the studies was at least six months. Our analysis demonstrated that neither non-EIAEAs nor EIAEDs exhibited superior seizure prophylaxis after glioma resection surgery. The pooled odds ratio was 1.12 (95% CI = 0.70-2.10, heterogeneity p = 0.420, I 2 = 0.0%). We also conducted a subset analysis of the studies according to the high-and low-grade glioma malignancy levels. However, most of the studies only reported the relative seizure control rates of the different drugs (e.g., LEV vs. PHY or VPA vs. PHY) and did not report the tumour histology. Therefore, we could not extract sufficient data to conduct a subset analysis of high-grade gliomas. The pooled odds ratio for non-EIAEDs vs. EIAEDs as seizure prophylaxes for lowgrade gliomas was 1.77 (95% CI = 0.71-4.40, p for heterogeneity = 0.982, I 2 = 0.0%); thus, the difference in the seizure control efficacies of NEIAEDs and EIAEDs for the treatment of patients with low-grade gliomas also failed to reach significance. We also conducted an analysis of LEV vs. PHY based on data from four studies. No significant heterogeneity was detected (p for heterogeneity = 0.430, I 2 = 0.0%), and the pooled odds ratio between the two AEDs was 1.459 (95% CI = 0.731-2.910). No significant asymmetries in the funnel plots were found in our analysis, which suggests the absence of publication bias, and the tests for publication bias produced p values greater than 0.25. However, these analyses were limited by the low number of studies (Figs. 2-4 ).
Discussion
In the present study, we systematically reviewed the relevant data and conducted a meta-analysis to determine whether P450 enzyme-inducing antiepileptic drugs control seizures more effectively than non-P450 enzyme-inducing antiepileptic drugs in glioma patients after surgery. We demonstrated that NEIAEDs and EIAEDs were not different in terms of their efficacies as seizure prophylaxis.
Seizure prevention and treatment have long been important services provided by neurosurgical units. The problems associated with seizure prevention and treatment are complex, and neurosurgeons should consider the interactions between antiepileptic and anticancer agents, the efficacy and side effects of antiepileptic drugs, the mechanisms of antiepileptic drugs, etc. Two previous meta-analyses have suggested that phenobarbital, phenytoin, and valproic acid prophylaxis exert no benefits in patients with brain tumours, but no specific meta-analysis of glioma patients had been previously conducted. 17, 18 Phenytoin, carbamazepine, sodium valproate, and levetiracetam are the AEDs that are most frequently used and studied by neurosurgeons, and these drugs are EIAEDs and NEIAEDs. Valproic acid (VPA) is one of the most-studied non-EIAEDs that are used to treat glioblastoma multiforme. VPA has been studied in vivo, in vitro and in clinical studies; however, the mechanisms underlying the possible benefits of VPA are not clear. Temozolomide is a prodrug and an imidazotetrazine derivative of the alkylating agent dacarbazine; the drug-to-drug interaction between VPA and temozolomide may reduce the clearance of temozolomide, which may increase its bioavailability or induce autophagy in vivo. 19 Another potential benefit of VPA may be due to its action as a histone deacetylase (HDAC) inhibitor. 20 As a 21 Another equally intriguing finding is the autophagy stimulated by valproic acid. Autophagy represents an alternative tumour-suppression mechanism that overcomes the strong resistance of malignant gliomas to radiotherapy and proapoptotic-related chemotherapy. 22 Levetiracetam (UCB Pharma, Inc.) is known as a secondgeneration AED and has been used to control seizures in patients with glioma. The mechanism underlying the anti-epileptic effect of LEV remains unclear, and most of the relevant studies have been conducted in clinical settings. With respect to seizure prophylaxis, Merr ell et al. found that levetiracetam and phenytoin have similar seizure control efficacies when used to treat patients with glioma. 23 Lim et al. also found no significant differences between levetiracetam and phenytoin in a randomised phase II pilot study. 4 Previous research has also shown that both VPA and LEV appear to have beneficial effects on verbal memory and limited side effects in glioma patients. 24 A number of investigators have also demonstrated that the serial monitoring of LEV is not required. Other non-EIAEDs, such as lamotrigine, have been less frequently used and studied in glioma patients. Phenytoin (PHY) and carbamazepine are considered to be the old generation of anti-epileptic drugs compared with newer antiepileptic drugs because they are not metabolised by the hepatic P450 system. 7 For decades, phenytoin has been the first choice for the control of glioma-related seizures (GAS) in many hospitals. Both phenytoin and carbamazepine are potent inducers, and the serum levels of many chemotherapeutic drugs, such as irinotecan, topotecan, teniposide, and thiotepa, may be significantly reduced by PHY or carbamazepine. 25 Moreover, corticosteroid metabolism is highly sensitive to enzyme induction. EIAEDs increase the metabolism of various steroids, which may lead to insufficient control of peritumoural edema. 26 Most of the side effects of phenytoin are well tolerated, and the most common side effects are rash, drowsiness, dizziness, and hirsutism. 27 The most feared side effect of phenytoin is Stevens-Johnson syndrome.
28 Table 2 Reasons of studies excluded in the meta-analysis. Our meta-analysis demonstrated that there is no difference between EIAEDs and NEIAEDs in terms of seizure control. The pooled odds ratio for NEIAEDs vs. EIAEDs was 1.12 (95% CI = 0.70-2.10) in patients with glioma, which means that the seizure activity occurrence rate in the NEIAED group was 1.12-fold higher than that of the EIAED group. However, taking a = 0.05 as the examination standard, this difference shows no statistical significance. However, the intriguing abovementioned results raise the question of whether non-P450 enzyme-inducing antiepileptic drugs, particularly LEV and VPA, should be routinely used to control seizures or prolong the lives of glioblastoma patients. The answer requires more information and careful consideration. Most of the results discussed were generated through unplanned retrospective analyses. The selection of the AEDs that were used depended on the investigators' preferences and local practices, although we did not find any evidence of bias. However, nonEIAEDs do have advantages in the treatment and prophylaxis of seizures in high-grade glioma patients. Non-EIAEDs do not affect anticancer agents when used as adjuvant treatments, and valproic acid may even elevate the plasma concentrations and toxic bone marrow effects of concomitant chemotherapeutic drugs. NonEIAEDs have been reported to induce fewer side effects. Moreover, the metabolism of the corticosteroids that are frequently used to control brain oedema is not increased by non-EIAEDs. Fortunately, additional data concerning this question may be available soon from a recently completed Radiation Therapy Oncology Group phase III trial (RTOG 0525) that compared the standard adjuvant temozolomide with a dose-dense regimen and from phase II trials of VPA (NCT00302159) and the HDAC inhibitor vorinostat (NCT00731731) with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma. We anxiously await the results of these international RCTs and hope that the results of these studies will enhance the treatment of glioblastoma-associated seizures. Additionally, more research studies on LEV need to be conducted.
We initially planned to perform a meta-analysis of glioma seizure prophylaxes and sought to evaluate the roles of nonEIAEDs and EIAEDs in the treatment of low-and high-grade gliomas. Compared with low-grade gliomas, GBMs and highgrade gliomas more frequently require chemotherapy, and we sought to examine the differences between NEIAEDs and EIAEDs in patients who had undergone standard chemotherapy. However, the available literature failed to provide adequate data for the conduction of sub-analyses of high-grade glioma or GBM despite our best efforts to contact the corresponding authors of all of the relevant papers. We also found that few RCTs have compared these two types of drugs. Thus, we recommend that more RCTs on this topic be performed. Because four of the six eligible studies found included comparisons between LEV and PHY, a sub-analysis of the differences between these two drugs was performed, and no significant difference in seizure prophylaxis was found.
Conclusions
The results of our study suggest that there is no significant difference between the efficacies of P450 enzyme-inducing and non-enzyme inducing antiepileptic drugs for late seizure prophylaxis. The sub-analysis revealed the following: (i) NEIAEDs and EIAEDs are not different in terms of seizure control in post-surgery patients with low-grade gliomas and (ii) levetiracetam and phenytoin exhibit similar seizure control efficacies. Further RCTs on this subject should be performed.
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